Genetic determinants of mycophenolate-related anemia and leukopenia after transplantation

Transplantation

Volumn 91, Issue 3, 2011, Pages 309-316

  Jacobson, Pamala A ^a   Schladt, David ^b   Oetting, William S ^a,c   Leduc, Robert ^b   Guan, Weihau ^b   Matas, Arthur J ^c   Lamba, Vishal ^b   Mannon, Roslyn B ^d   Julian, Bruce A ^d   Israni, Ajay ^e  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d University of Alabama at Birmingham   (United States)

^e HENNEPIN COUNTY MEDICAL CENTER   (United States)

Author keywords

Adverse effects; Anemia; Leukopenia; Mycophenolate; Mycophenolic acid; Pharmacogenetics; Pharmacogenomics; Toxicity; Transplantation

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVIRUS AGENT; AZATHIOPRINE; BASILIXIMAB; CAPTOPRIL; CLOPIDOGREL; CORTICOSTEROID; CYCLOSPORIN; CYTOCHROME P450 2C8; DACLIZUMAB; ENALAPRIL; ERYTHROPOIETIN; FLUOXETINE; FLUPHENAZINE; FONDAPARINUX; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; HEPARIN; INTERLEUKIN 12P35; IRON; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NUCLEIC ACID BINDING PROTEIN; PROTEIN HUS1; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; TICLOPIDINE; UNCLASSIFIED DRUG;

ADULT; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; CLINICAL TRIAL; DIALYSIS; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC VARIABILITY; HEMATOCRIT; HUMAN; KIDNEY TRANSPLANTATION; LEUKOCYTE COUNT; LEUKOPENIA; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHARMACOGENETICS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; ANEMIA; ARYL HYDROCARBON HYDROXYLASES; CELL CYCLE PROTEINS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-12 SUBUNIT P35; KIDNEY TRANSPLANTATION; LEUKOPENIA; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 79951512755     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318200e971     Document Type: Article

References (57)

1. Nogueras F, Espinosa MD, Mansilla A, et al. Mycophenolate mofetil-induced neutropeniain liver transplantation. Transplant Proc 2005; 37: 1509.
2. Danesi R, Del Tacca M. Hematologic toxicity of immunosuppressive treatment. Transplant Proc 2004; 36: 703.
3. Kuypers DR, Claes K, Evenepoel P, et al. Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients. Clin Pharmacol Ther 2004; 75: 434.
4. Le Meur Y, Buchler M, Thierry A, et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant 2007; 7: 2496.
5. van Gelder T, Hilbrands LB, Vanrenterghem Y, et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy oforal mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 1999; 68: 261.
6. Gaston RS, Kaplan B, Shah T, et al. Fixed- or controlled-dose myco-phenolate mofetil with standard- or reduced-dose calcineurin inhibitors: The opticept trial. Am J Transplant 2009; 9: 1607.
7. van Gelder T, Silva HT, de Fijter JW, et al. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: The fixed-dose concentration-controlled trial. Transplantation 2008; 86: 1043.
8. Anonymous. Myfortic [package insert]. East Hanover, NJ, Novartis Pharmaceuticals Corporation 2009.
9. Anonymous. Cellcept [package insert]. San Francisco, CA, Genentech 2010.
10. Kuypers DR, de Jonge H, Naesens M, et al. Current target ranges of mycophenolic acid exposure and drug-related adverse events: A5-year, open-label, prospective, clinical follow-up study in renal allograft recipients. Clin Ther 2008; 30: 673.
11. Galiwango PJ, Delgado DH, Yan R, et al. Mycophenolate mofetil dose reduction for gastrointestinal intolerance is associated with increased rates of rejection in heart transplant patients. J Heart Lung Transplant 2008; 27: 72.
12. Bunnapradist S, Lentine KL, Burroughs TE, et al. Mycophenolate mofetil dose reductions and discontinuations after gastrointestinal complications are associated with renal transplant graft failure. Transplantation 2006; 82: 102.
13. Knoll GA, MacDonald I, Khan A, et al. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol 2003; 14: 2381.
14. Ott U, Busch M, Steiner T, et al. Anemia after renal transplantation: An underestimated problem. Transplant Proc 2008; 40: 3481.
15. Gheith O, Wafa E, Hassan N, et al. Does posttransplant anemia at 6 months affect long-term outcome of live-donor kidney transplantation? A single-center experience. Clin Exp Nephrol 2009; 13: 361.
16. Chhabra D, Grafals M, Skaro AI, et al. Impact of anemia after renal transplantation on patient and graft survival and on rate of acute rejection. Clin J Am Soc Nephrol 2008; 3: 1168.
17. Hao C, Anwei M, Bing C, et al. Monitoring mycophenolic acid phar-macokinetic parameters in liver transplant recipients: Prediction of occurrence of leukopenia. Liver Transpl 2008; 14: 1165.
18. Kiberd BA, Lawen J,Fraser AD,etal. Early adequate mycophenolic acid exposure is associated with less rejection in kidney transplantation. Am J Transplant 2004; 4: 1079.
19. Atcheson BA, Taylor PJ, Kirkpatrick CM, et al. Free mycophenolic acid should be monitored in renal transplant recipients with hypoalbumin-emia. Ther Drug Monit 2004; 26: 284.
20. Weber LT, Shipkova M, Armstrong VW, et al. The pharmacokinetic- pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: A report of the German study group on mycophenolate mofetil therapy. J Am Soc Nephrol 2002; 13: 759.
21. Borrows R, Chusney G, Loucaidou M, et al. Mycophenolic acid 12-h trough level monitoring in renal transplantation: Association with acute rejection and toxicity. Am J Transplant 2006; 6: 121.
22. Wang J, Yang JW, Zeevi A, et al. IMPDH1 gene polymorphisms and association with acute rejection in renal transplant patients. Clin Pharmacol Ther 2008; 83: 711.
23. Ohmann EL, Burckart GJ, Brooks MM, et al. Genetic polymorphisms influence mycophenolate mofetil-related adverse events in pediatric heart transplant patients. J Heart Lung Transplant 2010; 29: 509.
24. Grenda R, Prokurat S, Ciechanowicz A, et al. Evaluation of the genetic background of standard-immunosuppressant-related toxicity in a cohort of200 paediatric renal allograft recipients -Aretrospective study. Ann Transplant 2009; 14: 18.
25. ChungF.Anti-inflammatory cytokines in asthma and allergy: Interleu-kin-10, interleukin-12, interferon-gamma. Mediators Inflamm 2001; 10: 51.
26. Jinushi M, Tahara H. Cytokine gene-mediated immunotherapy: Current status and future perspectives. Cancer Sci 2009; 100: 1389.
27. Gu Y, Zhang J, Peng J, et al. Elevated expression of IL-12 and IL-23 in patients with aplastic anemia. Int J Lab Hematol 2009; 31: 207.
28. Volkmer E, Karnitz LM. Human homologs of Schizosaccharomyces pombe rad1, hus1, and rad9 form a DNA damage-responsive protein complex. J Biol Chem 1999; 274: 567.
29. Zhou BB, Elledge SJ. The DNA damage response: Putting checkpoints in perspective. Nature 2000; 408: 433.
30. Daily EB, Aquilante CL. Cytochrome P450 2C8 pharmacogenetics: A review of clinical studies. Pharmacogenomics 2009; 10: 1489.
31. Muck W. Clinical pharmacokinetics of cerivastatin. Clin Pharmacokinet 2000; 39: 99.
32. Picard N, Cresteil T, Premaud A, et al. Characterization of a phase 1 metabolite of mycophenolic acid produced by CYP3A4/5. Ther Drug Monit 2004; 26: 600.
33. Papayannopoulou T, Craddock C, Nakamoto B, et al. The VLA4/ VCAM-1 adhesion pathway defines contrasting mechanisms of lodgement of transplanted murine hemopoietic progenitors between bone marrow and spleen. Proc Natl Acad Sci USA 1995; 92: 9647.
34. Koni PA, Joshi SK, Temann UA, et al. Conditional vascular cell adhesion molecule 1 deletion in mice: Impaired lymphocyte migration to bone marrow. J Exp Med 2001; 193: 741.
35. Picard N, Yee SW, Woillard JB, et al. The role of organic anion-transporting polypeptides and their common genetic variants in my-cophenolic acid pharmacokinetics. Clin Pharmacol Ther 2010; 87: 100.
36. Romaine SP, Bailey KM, Hall AS, et al. The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy. Phar-macogenomics J 2010; 10: 1.
37. Voora D, Shah SH, Spasojevic I, et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 2009; 54: 1609.
38. Link E, Parish S, Armitage J, et al. SLCO1B1 variants and statin-induced myopathy -A genomewide study. N Engl J Med 2008; 359: 789.
39. Johnson AD, Kavousi M, Smith AV, et al. Genome-wide association meta-analysis for total serum bilirubin levels. Hum Mol Genet 2009; 18: 2700.
40. XiangX,Jada SR,LiHH, et al. Pharmacogenetics ofSLCO1B1 gene and the impactof*1b and *15 haplotypesonirinotecan disposition inAsian cancer patients. Pharmacogenet Genomics 2006; 16: 683.
41. Innocenti F, Kroetz DL, Schuetz E, et al. Comprehensive pharmacoge-netic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol 2009; 27: 2604.
42. Sakaguchi S, Garcia-Bournissen F, Kim R,et al. Prolonged neutropenia after irinotecan-based chemotherapy in a child with polymorphisms of UGT1A1 and SLCO1B1. Arch Dis Child 2009; 94: 981.
43. Miura M, Satoh S, Inoue K, et al. Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacoki-netics in Japanese renal transplant recipients. Eur J Clin Pharmacol 2007; 63: 1161.
44. Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganci-clovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4: 611.
45. Akalin E, Sehgal V, Ames S, et al. Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis. Am J Transplant 2003; 3: 731.
46. Hartmann EL, Gatesman M, Roskopf-Somerville J, et al. Management of leukopenia in kidney and pancreas transplant recipients. Clin Transplant 2008; 22: 822.
47. Deeks ED, Keating GM. Rabbit antithymocyte globulin (thymoglobu-lin): A review of its use in the prevention and treatment of acute renal allograft rejection. Drugs 2009; 69: 1483.
48. Gaber AO, Monaco AP, Russell JA,etal. Rabbit antithymocyte globulin (Thymoglobulin): 25 years and new frontiers in solid organ transplantation and haematology. Drugs 2010; 70: 691.
49. Lam S, Partovi N,Ting LS, etal. Corticosteroid interactions with cyclo-sporine, tacrolimus, mycophenolate, and sirolimus: Fact or fiction? Ann Pharmacother 2008; 42: 1037.
50. Atcheson BA, Taylor PJ, Mudge DW, et al. Mycophenolic acid phar-macokinetics and related outcomes early after renal transplant. Br J Clin Pharmacol 2005; 59: 271.
51. Shipkova M, Spielbauer B, Voland A, et al. cDNA microarray analysis reveals new candidate genes possibly linked to side effects under my-cophenolate mofetil therapy. Transplantation 2004; 78: 1145.
52. Heller T, Geide A, Bonitz U, et al. Effect of the antioxidant idebenone on adverse events under mycophenolate mofetil therapy ina rat model. Transplantation 2008; 85: 739.
53. Gourishankar S, Leduc R, Connett J, et al. Pathological and clinical characterization of the 'troubled transplant': Data from the DeKAF study. Am J Transplant 2010; 10: 324.
54. Gaston RS, Kasiske BL, Fieberg AM, et al. Use of cardioprotective medications in kidney transplant recipients. Am J Transplant 2009; 9: 1811.
55. Matas AJ, Leduc R, Rush D, et al. Histopathologic clusters differentiate subgroups within the nonspecific diagnosesofCANorCR: Preliminary data from the DeKAF study. Am J Transplant 2010; 10: 315.
56. Van Ness B, Ramos C, Haznadar M, et al. Genomic variation in myeloma: Design, content, and initial application of the Bank On A Cure SNP Panel to detect associations with progression-free survival. BMC Med 2008; 6: 26.
57. Galwey NW. A new measure of the effective number of tests,a practical tool for comparing families of non-independent significance tests. Genet Epidemiol 2009; 33: 559.